Novartis AG (NYSE: NVS) announced Monday that it is adding to its immunomodulatory medicine portfolio with with an acquisition. What Happened Novartis said it's acquiring IFM Tre, a subsidiary of IFM ...

Novartis is handing over $310 million up front to acquire IFM Therapeutics’ inflammation-centered subsidiary, IFM Tre. The deal includes up to $1.265 billion in milestones and gives Novartis access to ...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...

Novartis has agreed to acquire a subsidiary of IFM Therapeutics for up to $1.575 billion, IFM said today, in a deal that will expand the pharma giant’s pipeline with one clinical and two pre-clinical ...